Home

“Slender IDS and Direct RX are extremely low profile, highly deliverable DES systems that provide excellent early and long-term clinical outcomes in complex patient populations. Slender IDS uses a unique DES delivery platform while both systems incorporate a novel drug carrier and other technologies which I believe will add value in the treatment of patients in the US,” said Dean Kereiakes, president of The Christ Hospital Heart & Vascular Institute in Cincinnati, USA, clinical professor of Medicine, The Ohio State University and co-principal investigator of the OPTIMIZE study.

In a press release, Svelte describes the Slender IDS as an ‘all-in-one’ integrated delivery system featuring Asahi guide wire technology, and Direct RX as a workhorse rapid-exchange delivery system. Both are low profile DES systems designed to enhance trans-radial intervention (TRI) and indicated by the FDA for use with direct stenting, the company adds.

“Materially lower system and crossing profiles facilitate TRI, which, when combined with a direct stenting approach in appropriate clinical indications, streamline procedures, limit complications and enhance patient experience,” added Sunil Rao, professor of Medicine at Duke University in Durham, USA and co-principal investigator of the OPTIMIZE study. “TRI has been long regarded as the standard of care overseas. With its increased adoption and use in the majority of cases recently in the US, approval of these products is very timely. I am excited to integrate them into my practice.”

Direct stenting was undertaken in 30% of OPTIMIZE subjects, with 96% device success rates observed. Eighty percent of study subjects were treated via TRI.

“OPTIMIZE was a unique study—the first of its kind to evaluate a new mode of DES delivery, a new class of drug coating, direct stenting and TRI. This not only generated outstanding data on investigational device performance, but also helped identify discrepancies between study definitions and assessments of myocardial infarction in clinical studies, which will help areas of future clinical research. We commend FDA for its timely and clear communications, understanding of technical and complex subject matter and true collaboration throughout the review process,” said Jack Darby, president and CEO of Svelte Medical Systems. “We thank all OPTIMIZE investigators for their contribution to the study and look forward to our newly approved DES systems delivering unmatched value to all constituents of cardiac care in the USA—patients, physicians, providers and payers.”

Source CardiovascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: Svelte Medical Systems receives US FDA approval for Slender IDS and Direct RX

Chia sẽ qua google bài: Svelte Medical Systems receives US FDA approval for Slender IDS and Direct RX

Chia sẽ qua twitter bài: Svelte Medical Systems receives US FDA approval for Slender IDS and Direct RX

Chia sẽ qua MySpace bài: Svelte Medical Systems receives US FDA approval for Slender IDS and Direct RX

Chia sẽ qua LinkedIn bài: Svelte Medical Systems receives US FDA approval for Slender IDS and Direct RX

Chia sẽ qua stumbleupon bài: Svelte Medical Systems receives US FDA approval for Slender IDS and Direct RX

Chia sẽ qua icio bài: Svelte Medical Systems receives US FDA approval for Slender IDS and Direct RX

Chia sẽ qua digg bài: Svelte Medical Systems receives US FDA approval for Slender IDS and Direct RX

Chia sẽ qua yahoo bài: Svelte Medical Systems receives US FDA approval for Slender IDS and Direct RX

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.